Beam Therapeutics Inc. (BEAM) Financial Statements (2025 and earlier)

Company Profile

Business Address 26 LANDSDOWNE STREET
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:1,200,0001,100,000965,600299,700
Cash and cash equivalents435,895232,767559,994162,171
Short-term investments   140,100
Other undisclosed cash, cash equivalents, and short-term investments764,105867,233405,606(2,571)
Other undisclosed current assets11,043(7,104)307,4078,621
Total current assets:1,211,0431,092,8961,273,007308,321
Noncurrent Assets
Operating lease, right-of-use asset112,846118,513102,71886,859
Property, plant and equipment124,960115,62084,25838,513
Restricted cash and investments8,71912,75412,74614,840
Other noncurrent assets2,1461,9311,7243,144
Total noncurrent assets:248,671248,818201,446143,356
TOTAL ASSETS:1,459,7141,341,7141,474,453451,677
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities55,01647,16429,42915,853
Employee-related liabilities11,6617,591
Accounts payable1,6179,0297,4746,314
Accrued liabilities53,39938,13510,2941,948
Deferred revenue68,706135,97486,270 
Debt  1,8532,2872,118
Derivative instruments and hedges, liabilities10,80018,30042,20071,200
Other undisclosed current liabilities71,04320,30453,24913,166
Total current liabilities:205,565223,595213,435102,337
Noncurrent Liabilities
Long-term debt and lease obligation  1,154137,817101,308
Finance lease, liability  1,1543,0075,294
Liabilities, other than long-term debt272,820383,491296,4632,471
Deferred revenue109,888202,179262,303 
Other liabilities2982242,7932,471
Operating lease, liability159,911168,625134,81096,014
Business combination, contingent consideration, liability2,72312,46331,367 
Derivative instruments and hedges, liabilities    
Total noncurrent liabilities:272,820384,645434,280103,779
Total liabilities:478,385608,240647,715206,116
Equity
Equity, attributable to parent981,329733,474826,738245,561
Common stock816712684573
Additional paid in capital2,169,7981,792,5541,594,378642,633
Accumulated other comprehensive income (loss)604(2,430)(50)(9)
Accumulated deficit(1,189,889)(1,057,362)(768,274)(397,636)
Total equity:981,329733,474826,738245,561
TOTAL LIABILITIES AND EQUITY:1,459,7141,341,7141,474,453451,677

Income Statement (P&L) ($ in thousands)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues377,70960,92051,84424
Gross profit:377,70960,92051,84424
Operating expenses(554,194)(399,399)(444,309)(132,784)
Operating loss:(176,485)(338,479)(392,465)(132,760)
Nonoperating income (expense)45,32478,30121,827(118)
Investment income, nonoperating29,7439,41075(118)
Loss from continuing operations before income taxes:(131,161)(260,178)(370,638)(132,878)
Income tax expense(1,366)(3,410)  
Other undisclosed loss from continuing operations    
Loss from continuing operations:(132,527)(263,588)(370,638)(132,878)
Loss before gain (loss) on sale of properties:(370,638)(132,878)
Other undisclosed net loss  (25,500) (61,714)
Net loss attributable to parent:(132,527)(289,088)(370,638)(194,592)
Preferred stock dividends and other adjustments    (1,277)
Net loss available to common stockholders, diluted:(132,527)(289,088)(370,638)(195,869)

Comprehensive Income ($ in thousands)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(132,527)(289,088)(370,638)(194,592)
Comprehensive loss:(132,527)(289,088)(370,638)(194,592)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent3,034(2,380)(41)(25)
Comprehensive loss, net of tax, attributable to parent:(129,493)(291,468)(370,679)(194,617)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: